Retour

GSK plc

Qualité des données : 100%

GSK

NYSE Healthcare Drug Manufacturers - General

51,99 €

▲ 0,16 € (0,30%)

Cap. Boursière : 104,42B

Également cotée sous GLAXF OTC

Fourchette du Jour

51,80 € 52,69 €

Fourchette 52 Semaines

32,38 € 61,70 €

Volume

4 212 688

Moyenne 50J / 200J

54,58 € / 45,66 €

Clôture Précédente

51,84 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique	Action	Médiane du Secteur
P/E	18,7	0,4
P/B	6,4	2,9
ROE %	37,3	3,8
Net Margin %	17,5	3,9
Rev Growth 5Y %	6,7	10,0
D/E	1,1	0,2

Objectif de Cours des Analystes

Hold

53,00 € +1.9%

P/E Prévisionnel

10,8

BPA Prévisionnel

4,80 €

Croissance BPA (est.)

+0,0%

CA Est.

46 B

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2030	5,85 € 5,67 € – 6,06 €	50 B	5
FY2029	5,96 € 5,77 € – 6,17 €	51 B	2
FY2028	5,55 € 5,00 € – 6,63 €	49 B	7

Insider Trading Activity

Buy ratio (90d) 0.0%

10 transactions

Date	Insider	Type	Shares	Price	Value
Mar 3, 2026	Braunstein Scott	sell	29 956	—	—
Mar 3, 2026	Dombkowski Ashley L.	sell	29 956	—	—
Mar 3, 2026	Lyons-Williams Lori	sell	47 240	—	—
Mar 3, 2026	Giordano Michael F	sell	48 328	—	—
Mar 3, 2026	Young Rodney KB CHIEF FINANCIAL OFFICER	sell	205 703	—	—
Mar 3, 2026	Kozick Linda	sell	51 762	—	—
Mar 3, 2026	Brockstedt Dirk G. CHIEF SCIENTIFIC OFFICER	sell	164 742	—	—
Mar 3, 2026	GRAY MARY ANN	sell	59 858	—	—
Mar 3, 2026	Wong Brian Russell PRESIDENT AND CEO	sell	827 353	—	—
Dec 11, 2025	GSK plc 10% Owner	buy	1 470 000	19,00 €	27 930 000 €

Points Clés

Revenue grew 6,65% annually over 5 years — modest growth

Earnings grew 117,12% over the past year

ROE of 37,25% indicates high profitability

Net margin of 17,50% shows strong profitability

Generating 5,82B in free cash flow

PEG of 0,11 suggests growth is underpriced

Croissance

Revenue Growth (5Y)

6,65%

Revenue (1Y)1,83%

Earnings (1Y)117,12%

FCF Growth (3Y)-3,52%

Qualité

Return on Equity

37,25%

ROIC15,45%

Net Margin17,50%

Op. Margin21,95%

Sécurité

Debt / Equity

1,08

Current Ratio0,82

Interest Coverage10,23

Valorisation

P/E Ratio

18,68

P/B Ratio6,39

EV/EBITDA16,93

Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	1,83%	Revenue Growth (3Y)	2,64%
Earnings Growth (1Y)	117,12%	Earnings Growth (3Y)	6,51%
Revenue Growth (5Y)	6,65%	Earnings Growth (5Y)	6,26%
Profitability
Revenue (TTM)	31,95B	Net Income (TTM)	5,59B
ROE	37,25%	ROA	9,16%
Gross Margin	72,54%	Operating Margin	21,95%
Net Margin	17,50%	Free Cash Flow (TTM)	5,82B
ROIC	15,45%	FCF Growth (3Y)	-3,52%
Safety
Debt / Equity	1,08	Current Ratio	0,82
Interest Coverage	10,23	Dividend Yield	0,03%
Valuation
P/E Ratio	18,68	P/B Ratio	6,39
P/S Ratio	3,27	PEG Ratio	0,11
EV/EBITDA	16,93	Dividend Yield	0,03%
Market Cap	104,42B	Enterprise Value	118,72B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	31,95B	31,38B	30,33B	29,32B	24,70B
Net Income	5,59B	2,58B	4,93B	14,96B	4,39B
EPS (Diluted)	2,72	1,24	2,40	2,40	2,70
Gross Profit	23,18B	22,33B	21,76B	19,77B	16,53B
Operating Income	7,01B	4,02B	6,75B	6,43B	4,36B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	61,01B	59,46B	75,22B	60,15B	107,14B
Total Liabilities	45,02B	46,38B	58,91B	50,05B	78,23B
Shareholders' Equity	16,35B	13,67B	17,01B	10,60B	20,39B
Total Debt	17,69B	16,99B	22,97B	20,99B	32,74B
Cash & Equivalents	3,39B	3,69B	3,74B	3,72B	5,79B
Current Assets	17,48B	17,00B	23,77B	20,77B	25,29B
Current Liabilities	21,35B	21,70B	26,86B	22,81B	32,06B